THT Conference 2025 - Outcomes after heart failure patients were treated with an interatrial shunt show heart failure with reduced ejection fraction (HFrEF) patients had further benefit compared to heart failure with preserved ejection fraction (HFpEF) patients. The study's prediction model revealed four independent predictors of two-year adverse outcomes in HFrEF patients treated with medical therapy alone and four different predictors in HFrEF patients treated with the shunt. In HFpEF patients, four independent predictors of two-year adverse outcomes were found in control-treated patients and six multivariable independent predictors were found after shunt treatment.

Dr Gregg Stone (Icahn School of Medicine at Mount Sinai, New York, NY, US) joins us to discuss the findings from RELIEVE-HF (NCT03499236), a placebo-controlled randomized study investigating the safety and effectiveness of the V-Wave Interatrial Shunt System (V-Wave Ltd) for patients with NYHA Class II, Class III, or ambulatory Class IV HFrEF or HFpEF who are on guideline-directed medical therapies. The study analysed univariable and multivariable baseline predictors of adverse events and created a risk score for the events in HFrEF patients treated with medical therapy or the interatrial shunt and HFpEF patients treated with medical therapy or the interatrial shunt.

Interview Questions:
1. What is the reasoning behind this study?
2. What was the patient population?
3. Could you tell us more about the study design and the key findings?
4. Were there any surprising or unexpected outcomes?
5. What further research is needed, and what are the next steps?

Recorded remotely from New York, 2025

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh

Support: This is an independent interview produced by Radcliffe Cardiology.